Members of the Senate health committee on Tuesday fired off questions at drug industry reps in the first of two hearings to deal with the latest five-year funding agreements that Congress has to re-authorize by the end of September and that the FDA relies on to review new drug, generic drug, biologic and biosimilar applications. … Continue reading Senators grill industry groups over FDA user fee agreements to fund the agency through 2027